PharmaEssentia Corporation announces presentation of the results of the phase II trial for P1101 + ribavirin in patients with chronic HCV genotype 1 infection at the 25 th Conference of the Asian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback